Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Keck School Scientists Design Mouse with More Human-Like Immune Response

Published: Wednesday, February 06, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
The discovery makes way for quicker and more cost-effective development of next-generation drugs to treat human diseases, such as cancer, diabetes and tuberculosis.

Medical researchers have long used mice and rats to help formulate new drugs and vaccines, in part because their genetic and biological characteristics closely parallel human physiology. But many experimental drugs that work extraordinarily well in rodents fail miserably when tested in people.

One such drug, α-galactosylceramide (α-GalCer), essentially wipes out cancerous tumors in mice by activating the body’s immune system; for reasons not entirely clear, the drug does not trigger the same response in people with cancer. Scientists hypothesize that this failure is due to subtle differences between the CD1d molecules in mice and humans and how they respond to tumors and infection. CD1d molecules are found on certain cells that trigger the body’s innate immune response.

In a study to be published this week by the Proceedings of the National Academy of Sciences, USC researchers describe how they genetically engineered mice to express CD1d molecules that look more like those in humans and in more similar proportions. More importantly, the humanized CD1d molecules effectively trigger natural killer T (NKT) cells — a recently discovered type of white blood cell that attacks tumors and infection — in live animals when exposed to α-GalCer.

“It’s the best model we have in the field,” said Weiming Yuan, assistant professor of molecular microbiology and immunology at the Keck School of Medicine of USC and principal investigator of the study. “We’ve basically set a platform to fast-track the identification of immunotherapies that can kill cancer and also make vaccines stronger.”

Once activated, NKT cells react in a matter of hours whereas other T cells may take days. This rapid response makes them difficult to study but also an ideal target for drug-makers. Yuan’s humanized mouse allows scientists to more accurately test the viability of those NKT cell-targeting drugs before going to human clinical trials.

“Before, it would have been a guess as to whether the drug would work in people. Now, the chance of success goes from one out of 100 to one out of five,” Yuan said.

Yuan and colleagues have yet to demonstrate the effects of inserting a more human-like version of the final component of the CD1d/NKT system, the T cell receptor. More experiments are necessary to determine why α-GalCer is ineffective in treating people with cancer and to develop novel α-GalCer derivatives that work with the human immune system.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Zika Proteins Responsible for Microcephaly Identified
Researchers have undertaken the first study to examine Zika infection in human neural stem cells from second-trimester fetuses.
Monday, August 22, 2016
Just Gellin’: How To Grow Strong Muscles-On-A-Chip
USC researchers hope to usher in new treatments for patients with muscular dystrophy.
Tuesday, July 05, 2016
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Monday, May 23, 2016
How Skeletal Stem Cells Form The Blueprint Of The Face
USC researchers discover that two types of molecular signals work to control where and when stem cells turn into facial cartilage.
Friday, May 06, 2016
Genes Connected to Well-Being, Depression and Neuroticism
The researchers found three genetic variants associated with subjective well-being — how happy or satisfied a person reports feeling about his or her life.
Wednesday, April 20, 2016
New Set of Aging Related Proteins
Tested in both mice and human cells, the proteins may lead to greater understanding of aging-related diseases, from diabetes to Alzheimer’s to cancer.
Wednesday, April 13, 2016
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Thursday, November 26, 2015
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Wednesday, November 11, 2015
Gene Changes That Affect Brain Size Identified
The identity of eight common mutations may one day reveal more about Alzheimer’s, autism and other neurological disorders.
Friday, January 23, 2015
How Gene Expression Affects Facial Expressions
Researchers from USC have demonstrated how a mutation in TBX1 causes facial deformities associated with DiGeorge Syndrome.
Tuesday, September 23, 2014
Cellular Automaton Model Predicts how Hair Follicle Stem Cells Regenerate
Your hair -- or lack of hair -- is the result of a lifelong tug-of-war between activators that wake up, and inhibitors that calm, stem cells in every hair follicle on your body, according to Cheng-Ming Chuong, M.D., Ph.D., of the University of Southern California (USC).
Friday, December 09, 2011
Cancer Cells, Stem Cells Share Same Origin, Researchers Say
USC scientists proved that oncogenes change normal cells into stem-like cells, paving the way to a safer and more practical approach to treating diseases with stem cell therapy.
Tuesday, July 26, 2011
JAK3 Pathway Highlighted as Leukemia Target
An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).
Friday, November 19, 2010
Embryonic Stem Cells from Rats Derived
The breakthrough finding will enable scientists to create more effective animal models for the study of a range of human diseases.
Monday, December 29, 2008
Abraxis BioScience Signs Licensing Agreement with University of Southern California
Abraxis exclusively licenses property portfolio designed to personalize treatment for colorectal cancer from the University of Southern California.
Wednesday, June 20, 2007
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Gene Therapy Going Global with Portable Device
Portable 'gene therapy in a box' could make future cancer and HIV cures affordable in developing countries.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
3D-Printed Heart-On-A-Chip with Integrated Sensors
Researchers have created the first 3D-printed organ-on-a-chip with integrated sensors, paving the way for more complex, customizable devices.
Wrapping up the Genome
Researchers successfully package complete yeast genome using purified components, yielding new insights into genome mechanisms.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Precision Medicine Guiding Cancer Patients’ Chemotherapy Decision
New study finds doctors use genetic test to measure breast cancer recurrence risk, make tailored treatment recommendations.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos